BeiGene Ltd. Sponsored ADR Stock

$274.78

1.38%

Nasdaq, Wed, Apr 02 2025

ISIN

US07725L1026

Symbol

BGNE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

BeiGene Ltd. Sponsored ADR Stock price

$274.78

+138.42 101.51% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

+3.74 1.38%

ISIN

US07725L1026

Symbol

BGNE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$27.17b
Enterprise Value	$25.61b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	6.72
P/S ratio (TTM) P/S ratio	7.13
P/B ratio (TTM) P/B ratio	8.80
Revenue growth (TTM) Revenue growth	54.96%
Revenue (TTM) Revenue	$3.81b
EBIT (operating result TTM) EBIT	$-568.20m
Free Cash Flow (TTM) Free Cash Flow	$-633.29m
Cash position	$2.64b
EPS (TTM) EPS	$-6.13
P/E forward	276.34
P/S forward	5.36
EV/Sales forward	5.05
Short interest	2.64%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

BeiGene Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

31 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

30x Buy

97%

More details on Analyst Estimates Including Price Targets

31 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

Buy

97%

Hold

Analyst Estimates with Stock Price Targets

Financial data from BeiGene Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	3,810 3,810	55% 55% 100%
- Direct Costs	723 723	56% 56% 19%
Gross Profit	3,087 3,087	55% 55% 81%
- Selling and Administrative Expenses	1,643 1,643	16% 16% 43%
- Research and Development Expense	1,840 1,840	8% 8% 48%
EBITDA	-396 -396	65% 65% -10%
- Depreciation and Amortization	172 172	96% 96% 5%
EBIT (Operating Income) EBIT	-568 -568	53% 53% -15%
Net Profit	-645 -645	27% 27% -17%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

BeiGene Ltd. Sponsored ADR Stock News

Neutral

Business Wire

●

3 days ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination...

Neutral

Business Wire

●

3 months ago

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment ...

Neutral

Business Wire

●

3 months ago

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. “As we enter our 15th year, ch...

More BeiGene Ltd. Sponsored ADR News

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Head office	Cayman Islands
CEO	John Oyler
Employees	11,000
Founded	2010
Website	www.beigene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now